Navigation Links
Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2010
Date:7/28/2009

remaining deficiencies. Products sold and distributed by Caraco that are manufactured outside of these facilities are not materially impacted. As a result of this event, there has been a material adverse effect on our current operations and may be a material adverse effect on our near term operations. We anticipate working with the FDA to resolve these concerns as effectively and expeditiously as possible."

The total value of the seized inventory is $22.9 million. Of such inventory, we have created a partial reserve in the amount of $8.4 million which consists of work in process relating to those materials which are in various stages of production within our manufacturing facilities, finished goods having a shelf life of one year or less as of June 30, 2009, and those products which will be difficult to recondition. Once we have further understanding and clarity from the FDA on the status of the entire inventory, we will make a determination of whether adjustments to the reserve need to be made.

We incurred a gross loss of $3.6 million during the first quarter of Fiscal 2010, as compared to gross profit of $23.6 million during the corresponding period of Fiscal 2009. The gross loss in the first quarter of Fiscal 2010 was primarily due to the $8.4 million inventory reserve and lower sales of manufactured and distributed products. "Although gross profit margins have decreased to a negative 7.5% for the first quarter of Fiscal 2010 as compared to 21.7% during the corresponding period of Fiscal 2009, due to the creation of the inventory reserve, lower sales, and the mix of distributed products weight over manufactured products, we believe we will remain competitive in marketing and distribution product sales and manufactured products sales that are manufactured by third parties," Mr. Movens said.

Selling, general and administrative ("SG&A") expenses during the first quarter of Fiscal 2010 were $3.7 million,
'/>"/>

SOURCE Caraco Pharmaceutical Laboratories, Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
2. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
4. Caraco Pharmaceutical Laboratories Ltd. Announces Tentative FDA Approval for Generic Zyrtec Chewable(R)
5. Caraco Pharmaceutical Laboratories Ltd. Reports Record Net Sales for the Second Quarter and First Six Months of Fiscal 2008
6. Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Generic Lamictal(R)
7. Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Generic Lexapro(R)
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Norvasc(R)
9. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Zyrtec Allergy Tablets(R) and Zyrtec Hives Relief Tablets(R)
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Childrens Zyrtec(R) Chewable Tablets for Allergy Relief and Childrens Zyrtec(R) Chewable Tablets for Hives Relief
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Metaglip(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2015)... 2015 Add High-Quality prismatic refractions into footage ... , It's as simple as dragging and dropping footage into ... for full effect. , Including over 80 stunning flares, ... sensors making this the ultimate bundle for adding prismatic refractions ... this package are movie files designed for Final Cut Pro ...
(Date:5/22/2015)... Utah (PRWEB) May 22, 2015 Mountain Point ... host a ribbon cutting ceremony on Friday, May 29, 2015 ... p.m. to 6 p.m. The new medical center, set to ... North Triumph Boulevard, Lehi, UT 84043. , “The opening ... our team and the Utah County community,” said Kent Loosle, ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 Combination ... treatment option for chronic obstructive pulmonary disorder (COPD) ... plc and AstraZeneca plc as well as Germany’s ... share and position. But will market payers, clinicians ... already well-entrenched products to completely new ones? , ...
(Date:5/22/2015)... 2015 Coordinating care for people ... Historically providers have not been reimbursed or rewarded ... 2015, Medicare has paved the way by offering ... the launch of Oculus Health , an ... using the platform will now be able to ...
(Date:5/22/2015)... 22, 2015 ZH Healthcare ... solutions, announced today that Bill Lane, joins ZH’s ... developer of BlueEHS,a first of its kind, Freemium ... customizable Electronic Health Records (EHR) with an integrated ... telemedicine-enabled comprehensive patient portal, and more. Combined with ...
Breaking Medicine News(10 mins):Health News:Developers at Pixel Film Studios Release ProFlare 5K Prism for Final Cut Pro X. 2Health News:Mountain Point Medical Center, a Campus of Jordan Valley Medical Center, Hosts Ribbon Cutting Ceremony and Community Celebration on Friday, May 29, 2015 2Health News:Chronic Obstructive Pulmonary Disorder Therapeutics Market Discussed in In-demand FirstWord Report Published at MarketPublishers.com 2Health News:Oculus Health Care Coordination Platform Officially Launched 2Health News:Oculus Health Care Coordination Platform Officially Launched 3Health News:Oculus Health Care Coordination Platform Officially Launched 4Health News:ZH Healthcare Adds Bill Lane to Advisory Board 2
... NRL: THE NEW STANDARDIZED SOURCE MATERIAL FOR THE PRODUCTION ... PRODUCTS USING ... Technology Limited has invited,Vystar Corporation to present its revolutionary ... Conference 2008 in Madrid in,January. "Vytex(TM) Natural Rubber ...
... Spain: In a surprising finding, American scientists have found ... as well as their single counterparts in certain aspects ... study, presented today (Wednesday) at the European Cancer Conference ... 489 patients with Barretts oesophagus, a non-cancerous condition linked ...
... that attacks cancer in an entirely new way has ... the disease and prolonging the lives of patients. , ... Conference (ECCO 14) in Barcelona found that giving the ... the amount of time patients survived without progression of ...
... and Vicksburg Plants Recognized as Premier,Facilities by the Association for ... ... Magazine, BATESVILLE, Ind., Sept. ... Hillenbrand Industries (HB),announced that its two metal manufacturing facilities and ...
... Proposals and Variations, LOS ANGELES, Sept. ... a leading e-health Wi-Fi PDA technology provider, ... and EMR applications,and the distributor of life ... products, announced today that its Board of ...
... newly incorporated subsidiary of Genomatix Software GmbH, has announced that ... the NCI/NIH for the fourth consecutive year. This years renewal ... was executed entirely between the US company and the NCI/NIH ... with our progress in putting the US company on its ...
Cached Medicine News:Health News:Global Latex Conference to Showcase Vytex(TM) NRL 2Health News:Married esophageal cancer patients fare worse in some quality of life aspects than single patients 2Health News:New type of drug shows promise in attacking melanoma in an innovative way 2Health News:Three Batesville Casket Company Production Facilities Honored for Manufacturing Expertise by National Organizations 2Health News:Three Batesville Casket Company Production Facilities Honored for Manufacturing Expertise by National Organizations 3Health News:InstaCare Corp. Reviewing M&A Plans 2
(Date:5/22/2015)... , May 22, 2015  Research and Benchmarking ... sixth Medical Affairs Roundtable on Thursday, ... a virtual roundtable to discuss "Medical Affairs, Role ... Best Practices, Medical Affairs Consortium provides Medical Affairs ... the key challenges they face. The consortium has ...
(Date:5/22/2015)... May 22 2015 /CNW/ - The Taskforce representing ... of all the hard work that the Minister and Health ... months. This program recognizes the needs of the thalidomide survivors, ... $75,000 a year, tax free, with annual adjustments for inflation. ... for annual payments of $100,000 based on the severity of ...
(Date:5/22/2015)... , May 22, 2015  Amgen (NASDAQ: ... has commenced termination of its participation in ... AstraZeneca (LON:AZN, STO:AZN and NYSE: AZN ... in development for patients with moderate-to-severe plaque ... decision was based on events of suicidal ...
Breaking Medicine Technology:Best Practices Sixth Medical Affairs Consortium Roundtable to Focus on Health Economics & Outcomes Research 2Amgen to terminate participation in co-development and commercialization of brodalumab 2Amgen to terminate participation in co-development and commercialization of brodalumab 3Amgen to terminate participation in co-development and commercialization of brodalumab 4Amgen to terminate participation in co-development and commercialization of brodalumab 5
... BLUE BELL, Pa., Feb. 2, 2011 Inovio Pharmaceuticals, ... in the development of therapeutic and preventive vaccines against ... a scientific paper in the journal Human Vaccines ... of Inovio,s SynCon™ DNA vaccine for prostate cancer targeting ...
... LIONVILLE, Pa., Feb. 1, 2011 West Pharmaceutical Services, Inc. ... attend the UBS 21st Annual Global Healthcare Services Conference in ... business and outlook on Tuesday, February 8, 2011 at 1:00 ... Company,s presentation, as well as a copy of the presentation ...
Cached Medicine Technology:Inovio Pharmaceuticals' Dual-Antigen SynCon™ DNA Vaccine for Prostate Cancer Induces Robust Responses in Preclinical Trial 2Inovio Pharmaceuticals' Dual-Antigen SynCon™ DNA Vaccine for Prostate Cancer Induces Robust Responses in Preclinical Trial 3Inovio Pharmaceuticals' Dual-Antigen SynCon™ DNA Vaccine for Prostate Cancer Induces Robust Responses in Preclinical Trial 4Inovio Pharmaceuticals' Dual-Antigen SynCon™ DNA Vaccine for Prostate Cancer Induces Robust Responses in Preclinical Trial 5
... drainage from the ureteropelvic junction to the ... segment with no sideports prevents postoperative narrowing ... of the ureteral wall to the stent. ... one-time use. CAUTION: Periodic evaluation is advised; ...
Used for retrograde positioning of a ureteral stent. The radiopaque band improves fluoroscopic visibility of the positioner tip. Supplied sterile in peel-open packages. Intended for one-time use....
... silicone or Silitek, ACMI Single J ... healing after surgery. Following cystectomy, the ... supports the ileal intestinal anastomosis, and ... leakage. Following ureteroscopy, the Single J ...
... The V-Max™ Roller Bar Electrode provides ... and improve visibility during TURP procedures. The ... surface with holes. The holes have circular ... tissue ablation. This patented design was developed ...
Medicine Products: